glp-1 treatment gonzales medications safe to continue before surgery in patients with diabetes and obesity GLP-1 Business Report for Healthtech

Semaglutide 2.4mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, placebo-controlled, phase 3 trial

The key differences: the FDA has not reviewed compounded semaglutide preparations for safety, effectiveness, or quality as finished products

One source says drink more water

Noom is best known for its eponymous app that helps people become healthier and lose weight by making changes to their diet and behaviours, and executive chair and former CEO Saeju Jeong said the move into providing semaglutide is "in line with our mission to help everyone everywhere live better longer." The company is offering compounded semaglutide for $149 for the first month and $279 for subsequent months, pairing the supply of the drug to its digital health platform to create a system that can achieve "sustainable, long-term weight loss" and help people eventually taper off treatment whilst keeping the weight off, said Jeong in a LinkedIn post

It is worth screening for